Cargando…

Sumatriptan (50 and 100 mg) in repeated migraine attacks: a patient preference study

Oral sumatriptan in 100-mg tablets is an effective and well tolerated treatment for the acute migraine attack. Since the launch of that dose, further studies have suggested good efficacy also for lower doses. This Italian multicentre study aimed at evaluating patient preference between the 50- and 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zanchin, Georgio, Roncolato, Maurizio, Fabbri, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag Italia 2000
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611708/ http://dx.doi.org/10.1007/s101940050007

Ejemplares similares

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study
por: Tfelt-Hansen, P., et al.
Publicado: (2006)

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine
por: Dahlöf, Carl, et al.
Publicado: (2004)

Influence of sumatriptan on the autonomic system during migraine attacks
por: Dalla Volta, G., et al.
Publicado: (2006)

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
por: Cady, Roger K., et al.
Publicado: (2017)

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
por: Tepper, Stewart J, et al.
Publicado: (2015)

Efficacy of oxygen inhalation in sumatriptan refractory “high altitude” cluster headache attacks
por: Mampreso, Edoardo, et al.
Publicado: (2009)

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
por: Brand-Schieber, Elimor, et al.
Publicado: (2016)

Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan
por: Newman, L C, et al.
Publicado: (2008)

The cost of the migraine patient in Italy
por: Roncolato, Maurizio, et al.
Publicado: (2000)

Efficacy of Sumatriptan/Placebo versus Sumatriptan/Propofol Combination in Acute Migraine; a Randomized Clinical Trial
por: Farahmand Rad, Reza, et al.
Publicado: (2022)

The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine
por: Wu, Jr-Wei, et al.
Publicado: (2022)

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
por: Moore, Johanna C, et al.
Publicado: (2012)

Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans
por: Diamond, S., et al.
Publicado: (2007)

Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial
por: Rahimdel, Abolghasem, et al.
Publicado: (2014)

Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients
por: Sternieri, E., et al.
Publicado: (2005)

Predicting Sumatriptan Responsiveness Based on Structural Connectivity in Patients Newly Diagnosed With Migraine
por: Lee, Dong Ah, et al.
Publicado: (2023)

Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
por: Landy, Stephen, et al.
Publicado: (2018)

Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study
por: Sandrini, G, et al.
Publicado: (2007)

Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal
por: Khoury, Chaouki K, et al.
Publicado: (2010)

Metoclopramide versus sumatriptan for treatment of migraine headache: A randomized clinical trial
por: Talabi, Saeid, et al.
Publicado: (2013)

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial
por: Falkenberg, Katrine, et al.
Publicado: (2018)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
por: Landy, Stephen, et al.
Publicado: (2018)

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder
por: Obaidi, Mohammad, et al.
Publicado: (2013)

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment
por: Tfelt-Hansen, Peer
Publicado: (2007)

Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study
por: Pini, Luigi Alberto, et al.
Publicado: (2012)

Metabolism of sumatriptan revisited
por: Pöstges, Timo, et al.
Publicado: (2023)

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs
por: Andre, Anthony D, et al.
Publicado: (2017)

Does repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache?
por: Dousset, Virginie, et al.
Publicado: (2004)

Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine
por: Kurul, Semra Hiz, et al.
Publicado: (2008)

The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats
por: Bulboacă, Adriana E, et al.
Publicado: (2018)

Managing migraine headaches experienced by patients who self–report with menstrually related migraine: a prospective, placebo–controlled study with oral sumatriptan
por: Dowson, A. J., et al.
Publicado: (2005)

Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
por: Tepper, Stewart J, et al.
Publicado: (2018)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

Application of Design of Experiment for Polyox and Xanthan Gum Coated Floating Pulsatile Delivery of Sumatriptan Succinate in Migraine Treatment
por: Jagdale, Swati C., et al.
Publicado: (2014)

Patient Factors in the Dose Selection of Oral Sumatriptan for Acute Migraine: A Post Hoc Analysis of Two Randomized Controlled Studies
por: Fisher, Matt, et al.
Publicado: (2023)

Assessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches
por: Gershovich, Olga E., et al.
Publicado: (2006)

The influence of weather on migraine – are migraine attacks predictable?
por: Hoffmann, Jan, et al.
Publicado: (2015)

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
por: Munjal, Sagar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i751rs1ihp5iriisb3mbkpvm3j